BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair

PARP inhibitors have been approved for the therapy of cancers with homologous recombination (HR) deficiency based on the concept of “synthetic lethality”. However, glioblastoma (GBM) patients have gained little benefit from PARP inhibitors due to a lack of BRCA mutations. Herein, we demonstrated tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Shaolu, Peng, Xin, Li, Xiaofei, Liu, Hongyan, Zhao, Baoquan, Elkabets, Moshe, Liu, Yao, Wang, Wei, Wang, Ran, Zhong, Yuxu, Kong, Dexin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150626/
https://www.ncbi.nlm.nih.gov/pubmed/34039959
http://dx.doi.org/10.1038/s41419-021-03805-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150626/
https://www.ncbi.nlm.nih.gov/pubmed/34039959
http://dx.doi.org/10.1038/s41419-021-03805-6

Ejemplares similares